Trending...
- Leadership in Democracy Cohort 2021 Announced
- Decorating "Things" has never been easier!
- Press 'Reset' For 2021 With New 'Cosmic Love Letters' Horoscopes
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on November 25, 2020, the Compensation Committee of Xeris' Board of Directors granted non-qualified stock options for an aggregate of 18,000 shares, and restricted stock units for an aggregate of 70,200 shares, of its common stock to 11 new employee(s) under Xeris' Inducement Equity Plan.
Xeris' Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to such individual's entering into employment with Xeris or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. The non-qualified stock options will vest over a period of four years, either 25% on the first anniversary of the grant with the remaining 75% vesting in thirty-six equal monthly installments thereafter, or 36% on 18 months after the grant date with the remaining 64% vesting in ten equal quarterly installments thereafter, and are subject to the employees' continued employment with Xeris or one of its subsidiaries. The restricted stock units will vest over a period of four years in equal annual installments, and are subject to the employees' continued employment with Xeris or one of its subsidiaries. All equity awards are subject to the terms and conditions of Xeris' Inducement Equity Plan and forms of award agreements covering the grants.
More on illi News
About Xeris Pharmaceuticals, Inc.
Xeris (Nasdaq: XERS) is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world.
With a novel technology platform that enables ready-to-use, room-temperature stable formulations of injectable and infusible therapies, the company is advancing a portfolio of solutions in various therapeutic categories, including its first commercial product, Gvoke®. Its proprietary XeriSol™ and XeriJect™ formulation technologies have the potential to offer distinct advantages over conventional product formulations, including eliminating the need for reconstitution, enabling long-term, room-temperature stability, significantly reducing injection volume, and eliminating the requirement for intravenous (IV) infusion. With Xeris' technology, new product formulations are designed to be easier to use by patients, caregivers, and health practitioners and help reduce costs for payers and the healthcare system.
More on illi News
Xeris is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on Twitter, LinkedIn or Instagram.
Xeris' Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to such individual's entering into employment with Xeris or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. The non-qualified stock options will vest over a period of four years, either 25% on the first anniversary of the grant with the remaining 75% vesting in thirty-six equal monthly installments thereafter, or 36% on 18 months after the grant date with the remaining 64% vesting in ten equal quarterly installments thereafter, and are subject to the employees' continued employment with Xeris or one of its subsidiaries. The restricted stock units will vest over a period of four years in equal annual installments, and are subject to the employees' continued employment with Xeris or one of its subsidiaries. All equity awards are subject to the terms and conditions of Xeris' Inducement Equity Plan and forms of award agreements covering the grants.
More on illi News
- Brazil's ANVISA Grants Novel Food Approval for NEM® brand eggshell membrane
- CreditSnap, a next generation FinTech startup, announces strategic seed investment from multi-lender finance platform Tresl, its earliest adopter
- Hilco Redevelopment Partners' Cori Rosales Accepted to the Chicago City Council Latino Caucus Foundation Leadership Academy 2021 Cohort
- Qué es el Marketing Science y por qué es indispensable considerarlo en el 2021
- Sterling Trading Tech Processed A Record 8.2% Of All Traded US Stock Volume
About Xeris Pharmaceuticals, Inc.
Xeris (Nasdaq: XERS) is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world.
With a novel technology platform that enables ready-to-use, room-temperature stable formulations of injectable and infusible therapies, the company is advancing a portfolio of solutions in various therapeutic categories, including its first commercial product, Gvoke®. Its proprietary XeriSol™ and XeriJect™ formulation technologies have the potential to offer distinct advantages over conventional product formulations, including eliminating the need for reconstitution, enabling long-term, room-temperature stability, significantly reducing injection volume, and eliminating the requirement for intravenous (IV) infusion. With Xeris' technology, new product formulations are designed to be easier to use by patients, caregivers, and health practitioners and help reduce costs for payers and the healthcare system.
More on illi News
- eHealth Market worth $193.8 billion by 2025 - Exclusive Report by MarketsandMarkets™
- Aesthetic Mentor Hosts Free Webinar "Becoming an Aesthetic Nurse in 2021"
- Affinitiv and Gubagoo Partner to Integrate Trade-In Valet Express into Digital Retailing Solution
- Process Technology announces advanced heating for IPA and flammable solvents with two new heaters
- Syxsense Announces the Release of Syxsense Cortex, A Next-Generation, Visual IT and Security Management Process Automation Solution
Xeris is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on Twitter, LinkedIn or Instagram.
Filed Under: Business
0 Comments
Latest on illi News
- Cardinal Dolan offers lessons of hope and courage in new book for Lent
- White Palms Fire Equipment Doubles Down on Online Presence By Hiring Leading Digital Marketing Company, Simply the Best Digital
- Silver Glen Senior Living Opens Doors to Residents in South Elgin, Illinois
- ACAMS' 4th Anti-Financial Crime Conference – Africa to Host Leading Compliance Experts on Region's Greatest Emerging Regulatory Risks
- Aon finds climate-influenced weather is key driver of $268B global damage from 2020 natural disasters with 64% uninsured
- Catch The Vibe: Astrologer Anne on Vibe Selection Podcast
- It's Undebatable: Astrologer Anne Shines On Super Fun Podcast
- Prism Health Lab Opens Their 6th Location at the Chinatown Branch of the Chicago Public Library, Enabling Easily Accessible COVID-19 Testing
- Six Features a D3P Needs to Make the Cloud 17a-4 Compliant
- Prime Law Group Hires New Attorney Mario J. Sankis
- Air Fry Plus: Enjoy Convenience And Style With Premium Kitchen Supplies
- Motorola Solutions to Issue Fourth-Quarter and Full-Year 2020 Earnings Results on Feb. 4
- Royal DSM Selects MAAG Group for Expansion in Strand Pelletizing Business
- Using Pandemic Lessons and Risk Assessments to Prepare for PCI DSS 4.0
- Press 'Reset' For 2021 With New 'Cosmic Love Letters' Horoscopes
- Kaizen Finance Launches Staking to Foster the Widespread Adoption of DeFi
- Ismail Sirdah Describes the Best Practices for Holding Corporate Events
- MDAdvantage Appoints Pete Cammarano to Board of Directors
- Leadership in Democracy Cohort 2021 Announced
- CEO Coaching International Congratulates Client Orion Energy on Successful Capital Partnerships